CYP2D6 polymorphisms influence tamoxifen treatment outcomes in

Pharmacogenetics of tamoxifen therapy in Asian populations: from genetic polymorphism to clinical outcomes

PDF) Evaluation of Endometrial Thickness and Bone Mineral Density Based on CYP2D6 Polymorphisms in Turkish Breast Cancer Patients Receiving Tamoxifen Treatment

CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis

Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen

Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?, Expert Reviews in Molecular Medicine

Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of CYP2D6-Mediated Tamoxifen Metabolism

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta‐Analysis of Heterogeneous Study Populations - Province - 2014 - Clinical Pharmacology & Therapeutics - Wiley Online Library

Full article: Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment

Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai brea

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial - ScienceDirect